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Present cell culture medium supplements, in most cases based on animal sera, are 
not fully satisfactory especially for the in  vitro expansion of cells intended for human 
cell therapy. This paper refers to (i) an heparin-free human platelet lysate (PL) devoid 
of serum or plasma components (v-PL) and (ii) an heparin-free human serum derived 
from plasma devoid of PL components (Pl-s) and to their use as single components or 
in combination in primary or cell line cultures. Human mesenchymal stem cells (MSC) 
primary cultures were obtained from adipose tissue, bone marrow, and umbilical cord. 
Human chondrocytes were obtained from articular cartilage biopsies. In general, MSC 
expanded in the presence of Pl-s alone showed a low or no proliferation in comparison 
to cells grown with the combination of Pl-s and v-PL. Confluent, growth-arrested cells, 
either human MSC or human articular chondrocytes, treated with v-PL resumed prolif-
eration, whereas control cultures, not supplemented with v-PL, remained quiescent and 
did not proliferate. Interestingly, signal transduction pathways distinctive of proliferation 
were activated also in cells treated with v-PL in the absence of serum, when cell pro-
liferation did not occur, indicating that v-PL could induce the cell re-entry in the cell cycle 
(cell commitment), but the presence of serum proteins was an absolute requirement for 
cell proliferation to happen. Indeed, Pl-s alone supported cell growth in constitutively 
activated cell lines (U-937, HeLa, HaCaT, and V-79) regardless of the co-presence of 
v-PL. Plasma- and plasma-derived serum were equally able to sustain cell proliferation 
although, for cells cultured in adhesion, the Pl-s was more efficient than the plasma 
from which it was derived. In conclusion, the cells expanded in the presence of the new 
additives maintained their differentiation potential and did not show alterations in their 
karyotype.
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2
Muraglia et al. Platelet- and Plasma-Derived Supplements
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org November 2017 | Volume 5 | Article 66
inTrODUcTiOn
Present cell culture medium supplements, in most cases based on 
animal sera, are not fully satisfactory. The adoption of an animal-
free culture medium is particularly relevant in establishing 
culture conditions for isolation and expansion of cells intended 
for clinical applications. Platelet growth factors can support cell 
proliferation and differentiation and human platelet derivatives 
were proposed as tissue culture supplements alternative to fetal 
calf or fetal bovine serum (FCS or FBS). Platelet derivatives used 
as cell culture medium supplements, are commonly provided in 
the form of platelet lysate (PL) within a small amount of plasma.
Plasma is the physiological fluid of blood and serum is the 
fluid remaining from plasma after fibrinogen, prothrombin, 
and other clotting factors have been removed. In vivo, cells are 
normally exposed to plasma and come in contact with serum 
only at the time of clot formation following an injury. Though, 
the use of plasma in cell culture presents some problems. Citrate, 
a calcium chelator, is the standard plasma anticoagulant used in 
the process of blood and plasma collection, but fibrin clots may 
still form when plasma is added to culture media, which contain 
calcium (Ayache et al., 2006). This is often prevented by adding 
heparin to the PL (Kocaoemer et al., 2007). However, heparins are 
active factors that bind growth factors and may interfere with cell 
growth (Vannucchi et al., 1990; Tiozzo et al., 1991; Cavari et al., 
1993; Khorana et al., 2003). Heparin negatively affected prolifera-
tion and motility of vascular smooth muscle cells (Mishra-Gorur 
and Castellot, 1999; Gilotti et  al., 2014) and inhibited growth 
of osteoblasts and MSC under conventional culture conditions 
(Andress, 1995; Handschin et al., 2005; Papathanasopoulos et al., 
2011). It was also shown that a relatively high concentration of 
heparin in culture media supplemented with human PL impaired 
adipogenic and osteogenic differentiation of mesenchymal stem 
cells (MSC) (Hemeda et al., 2013). Others reports showed that 
heparin interfered with the functional capacity for migration and 
homing of BM-derived mononuclear cells used in cardiovascular 
repair (Seeger et  al., 2012). Moreover, commercially available 
heparin is manufactured primarily from porcine sources and, 
being of animal origin, it represents a limit in the development 
of a totally xeno-free medium. Although porcine heparin is 
approved for human use, there are examples of hypersensitivity 
to the molecule (Bottio et al., 2003; Huang et al., 2012).
To overcome the need of heparin to prevent clotting after 
PL addition to the culture medium, different options, including 
the use of serum, were proposed. In principle, a human serum 
could be obtained by letting fresh whole blood, collected without 
any anticoagulant, to clot several hours before high-speed cen-
trifugation. Being deprived of coagulation factors, this serum, 
containing also platelet factors, can be added to the cell culture 
medium without that fibrin clots may form. However, this way 
one can obtain only small aliquots of PL, mainly for research use. 
In fact, this type of strategy does not allow the preparation of 
large batches of standardized, quality controlled PL starting from 
outdated blood donations. Indeed, an adopted approach is the 
production of a serum-converted PL from pooled platelet-rich 
plasma (PRP) derived from buffy coats (BC), i.e., fractions of 
blood which are by-products of plasma preparations routinely 
performed in the Blood Banks. The plasma-coagulation step is 
obtained by the addition of calcium chloride and/or thrombin 
(in most cases of animal origin). However, by this procedure, 
the relative concentration of factors before and after coagulation 
can vary. When the concentration levels of 100 soluble factors 
were measured in plasma and serum using a multiplexed ELISA 
assay, a comparison revealed that concentrations of two factors 
were higher in plasma, whereas the concentrations of 18 factors, 
including 11 chemokines, were higher in serum (Ayache et al., 
2006). Conflicting results exist in the literature with regard to the 
comparison of the biological activities of plasma and its derived 
serum. Mojica-Henshaw et  al. (2013) reported that PL-serum 
was less efficient than the sister counterpart PL-plasma in sup-
porting MSC proliferation although both lysates supported the 
cell tri-lineage differentiation potential. A beneficial effect of the 
fibrinogen-depleted lysate was instead observed with regard to 
the immunosuppressive properties of MSC (Copland et al., 2013).
An additional possibility to avoid the use of heparin is the 
production of a PL devoid of plasma through repeated cycles of 
platelet washing with a saline solution prior their rupture and 
release of bioactive factors. This PL sustained cell proliferation, 
comparable to FBS, in short-term (1–7 days) cultures of renal 
epithelial cells, of either animal or human origin, in adhesion 
and of human lymphoblastoid cells in suspension (Rauch et al., 
2011). The mitogenic effect induced by the PL addition was 
visualized also by the activation of the ERK1/2 factors. However, 
the sustainability of long-term cell expansion in the presence of 
PL obtained from washed platelets was not investigated and no 
experimental evidence was given in the published reports of a 
long-term cell culture in the continuous presence of a plasma-
free or serum-free PL as the only medium supplement.
As mentioned above, serum is usually obtained by allowing 
a whole blood specimen to clot prior to centrifugation. The first 
studies, using human serum obtained by conventional blood 
coagulation as cell culture supplement, showed the efficient 
isolation and expansion of bone marrow MSC that maintained 
their osteo-adipogenic differentiation potential (osteogenic 
differentiation was higher in autologous serum rather than in 
FBS) (Stute et  al., 2004). Furthermore, bone-marrow-derived 
MSC expanded in the presence of autologous human serum 
from whole blood presented a higher cell motility compared 
with the ones expanded in the presence of FCS (Kobayashi et al., 
2005). Autologous serum was shown to be a suitable supplement 
also for the in vitro expansion of dental pulp stem cells without 
altering their multi-lineage differentiation ability (Pisciotta et al., 
2012). In some cases, serum was also successfully derived by the 
clotting of umbilical cord whole blood. Human MSC from bone 
marrow and umbilical cord, isolated and expanded in allogenic 
cord blood serum (CBS) displayed higher self-renewal and a 
delayed senescence compared to cells cultured in fetal bovine 
serum (Shetty et al., 2007). Moreover, MSC cultured in the pres-
ence of CBS showed an enhanced and accelerated osteogenic 
differentiation and a repressed adipogenic differentiation (Jung 
et al., 2009). Off the clot AB serum is commercially available and 
was successfully used for isolation and expansion of cells, such 
as bone marrow MSC and hematopoietic stem cells (Anselme 
et al., 2002; Yamaguchi et al., 2002). Allogenic human AB-serum 
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was successfully used also for adipose MSC long-term culture 
(Kocaoemer et  al., 2007). Contradictory results, however, have 
been reported on the use of allogeneic human serum (Shahdadfar 
et al., 2005; Le Blanc et al., 2007; Tateishi et al., 2008; Turnovcova 
et al., 2009).
Alternatively, serum can be derived from blood plasma that 
has been treated with anticoagulants and from which blood 
cells, including red blood cells, white blood cells, and platelets, 
were removed by centrifugation [platelet-poor plasma (PPP)] 
or by plasma directly collected by apheresis. Also in this case, 
coagulation is obtained by addition of calcium cations and/or 
thrombin treatment. However, depending on the protocols to 
obtain the PPP, preparations may contain residual platelets and, 
when present, these residual platelets are activated during the 
centrifugation steps and the coagulation process and undergo a 
degranulation of the alpha granules, resulting in the release of 
their growth factor content. Therefore, the level of platelet growth 
factors in the final serum may change depending on the pres-
ence of platelets in the source material and this may significantly 
change the biological effect of serum when used as supplement in 
a cell culture medium. Tanaka et al. described a more pronounced 
stimulation of proliferation of human auricular chondrocytes 
when a serum derived from plasma, including platelets was 
compared to a serum derived from a plasma depleted of platelets 
although no significant differences were observed on the cartilage 
matrix deposition by chondrocytes under the different serum 
conditions (Tanaka et al., 2008). Recently, a comparison was per-
formed between two different plasma sources to obtain human 
serum, plasma removed from blood after 24  h from collection 
and plasma devoid of cryoprecipitate. Serum was obtained 
after coagulation in the presence of calcium ions. Both forms of 
plasma-derived serum were effective in sustaining fetal umbilical 
cord matrix derived MSC proliferation as the standard supple-
ment bovine serum (Dos Santos et al., 2017).
The different abilities of plasma and serum to modulate cell 
growth was investigated already in the 1970s. Initial studies 
indicated that cells did not proliferate in plasma containing 
medium, but they proliferated actively when they were exposed 
to serum (Balk et  al., 1973). However, the initial comparison 
was made between platelet-free plasma and serum containing 
platelet mitogens. Indeed, the addition of platelets and calcium to 
platelet-free plasma increased the activity of the obtained plasma-
serum to the same level achieved with blood serum (Ross et al., 
1974). Also the tridimensional environment to which cells are 
exposed to is crucial in modulating cell behavior. Gospodarowicz 
and Ill (1980) reported that bovine vascular smooth muscle cells 
in Petri dishes exposed to plasma proliferated poorly compared 
to when exposed to serum from whole blood, but, when the 
same cells were seeded on ECM-coated dishes, they proliferated 
equally well in the presence of either plasma or serum. Since this 
pioneering work, taking advantage of different cell types, different 
substrates, and different culture conditions, other authors have 
investigated the abilities of plasma and serum to promote cell 
growth (Stute et al., 2004; Shahdadfar et al., 2005; Mizuno et al., 
2006). Published results are sometimes contradictory. However 
some general conclusions can be made out of these publications: 
(i) platelet-depleted plasma or serum derived from this plasma 
are poor cell growth inducers in cultures of primary cells (Ross 
et al., 1974, 1978; Gajdusek et al., 1980); (ii) serum allows a better 
adhesion of the cells to the substrate than plasma, unless a coating 
of the culture dishes by serum or extracellular matrix proteins is 
adopted.
Several years ago, Rutherford and Ross (1976) reported that 
exposure of quiescent cells to whole blood serum or platelet-free 
plasma-serum plus crude platelet factors preparations stimulated 
cell proliferation. However, no accurate investigations were ever 
made to distinguish between the role played by factors and 
molecules released by platelets and the serum components. Aim 
of our experimental study was to verify the role played by PL 
devoid of plasma or serum contaminants (v-PL) and/or plasma or 
plasma-derived serum (Pl-s), used as supplements to the culture 
media, on the viability, proliferation kinetic and differentiation 
potential of MSC derived from human tissue. The effect on the 
proliferative capability of these blood-derived components was 
also tested on several cell lines. We report that, although factors 
and molecules released by platelets (PL in saline solution) were 
capable of activating the cell proliferation machinery (ERK and 
AKT phosphorylation, Cycline D1 induction, etc.) the PL itself 
used as single additive to the culture medium was unable to sup-
port cell proliferation unless the plasma or serum components 
were also present in the culture medium. Interesting, in cells 
that were constitutively stimulated, such as different cell lines of 
human or animal origin, or in some cultures of cells derived from 
fetal tissues, the addition of PL to the culture medium was not an 
absolute requirement and cell proliferation could be obtained by 
the simple addition of PL-free serum.
MaTerials anD MeThODs
Production of Virgin-Platelet lysate  
(v-Pl) and Plasma-serum (Pl-s)
An outline of the manufacturing process is reported in Figure 1. 
All separation steps were made within a sterile closed system. 
The high-speed centrifugation of a whole blood unit separates 
different phases: the plasma at the top, the buffy coat (BC) layer 
(enriched in platelets and leukocytes) at the interface and the 
red blood cells fraction at the bottom. For the preparation of the 
virgin-Platelet Lysate (v-PL), pools of BC units (not usable for 
transfusion purposes; up to 300 total units) were centrifuged at 
low speed. The PRP was recovered from the upper part of the blood 
bag and high-speed centrifuged to separate an upper phase, the 
PPP and a lower phase, the platelet concentrate. Recovered plate-
lets were subjected to three washes in sterile saline solution. After 
the third wash, the platelet concentrate was suspended in saline 
solution and the platelet concentration adjusted to 10 × 106 plt/μl. 
The platelet concentrate underwent three freeze–thaw cycles. A 
high-speed centrifugation was then performed to sediment plate-
let membranes and debris. The different obtained supernatants, 
the plasma-free platelet lysates (v-PL) were combined in a single 
pool before being divided into aliquots and lyophilized.
The Plasma-serum (Pl-s) was obtained from several frozen 
plasma units. Each plasma unit was slowly thawed at 4°C to 
separate the cryoprecipitate and the cryo-poor plasma (CPP). 
FigUre 1 | Manufacturing process outline. Steps in this procedure occur within a sterile closed system thanks to the possibility of performing sterile connections 
between blood bags.
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The CPP was added of calcium chloride (2  mg/ml) and then 
subjected to a coagulation step at 37°C up to 6  h. After the 
coagulation step, the blood bag was high-speed centrifuged to 
separate the coagulum. The liquid phase, the plasma-serum 
(Pl-s), was recovered, and the pool of 3–10  units was divided 
into aliquots and lyophilized. Pl-s and v-PL were frozen at −20°C 
and exposed to the freeze-drying procedure by means of the Heto 
LYOPRO 3000 (Analytical Control De Mori, Milano) apparatus. 
The lyophilization process was conducted for about 20  h until 
the water content was completely sublimated and the vials were 
closed under vacuum environment.
Both lyophilized products were stored at −20°C until use 
and generally used for the experiments within 3–4 months from 
their production.
cultures of human Msc and human  
cell lines
The use of human samples was approved by the institutional 
Ethics Committee of the Ospedale Policlinico San Martino, 
Genoa, Italy and done in accordance with the Helsinki 
Declaration of 1975.
Primary cultures of human MSC of different origin were 
established from biopsies of discarded surgical samples, 
lipoaspirates for cosmetic reasons, bone marrow of patients who 
underwent orthopedic surgery or cord blood of healthy moth-
ers. The patient/donor-informed consent was obtained prior 
sample processing. Human bone marrow-derived mesenchymal 
stem cells (BM-MSC) were obtained from bone marrow sam-
ples and adipose-derived mesenchymal stem cells (AD-MSC) 
were derived from liposuction waste according to published 
procedures (Muraglia et al., 2015). Umbilical cord-derived MSC 
(UC-MSC) were kindly provided by Dr. Introna M. (AO Papa 
Giovanni XXIII USS Center of Cell Therapy “G. Lanzani” USC 
Hematology, Bergamo, Italy). Cells were isolated from cord blood 
tissue collected from pregnant women after either normal vaginal 
delivery or Cesarean sections. The UC processing was performed 
in accordance with the protocol for the isolation and expansion 
of UC-MSC as previously described (Capelli et al., 2011). Primary 
cultures of cells derived from adult tissues (AD-MSC, age range: 
50–60 years, female; BM-MSC, age range: 33–60 years, male and 
female; UC-MSC, age range: 30–40 years, female. Number of cell 
cultures, n, is indicated in the legend of the figures for each cell 
type) were initially isolated and expanded in 10% FCS (passage 0). 
5
Muraglia et al. Platelet- and Plasma-Derived Supplements
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org November 2017 | Volume 5 | Article 66
The experiments were performed on cells derived from different 
donors. At the time of the first passage, the culture medium was 
replaced with medium supplemented with Pl-s and v-PL in dif-
ferent relative ratios and the cultures continued by passaging the 
cells before they reached confluence for about 30 days.
Cell lines U-937 and HeLa were purchased from the Interlab 
Cell Line Collection of the Biological Bank and Cell Factory of 
the Ospedale Policlinico San Martino (Genoa, Italy). HaCaT cell 
line was kindly provided by Dr. Pellegrini G. (Centro di Medicina 
Rigenerativa “Stefano Ferrari” Modena, Italy).
Basal medium for primary cell cultures was α-MEM (Lonza, 
Belgium), whereas cell line basal medium was MEM (EBSS) for 
HeLa cells, DMEM for HaCaT, and V-79 cells and RPMI for U-937 
cells (all from Euroclone, Italy). In all cases, the basal medium was 
supplemented with 100 IU/ml penicillin and 100 µg/ml strepto-
mycin, 2 mM l-glutamine and, where indicated, with Pl-s and 
v-PL used alone or in different combinations (5% v-PL alone or 
10% Pl-s or 10% Pl-s + 1% v-Pl or 10% Pl-s + 5% v-PL). In some 
control experiments, medium was supplemented with 10% fetal 
calf serum (FCS, Invitrogen, USA) instead of Pl-s and v-PL. Cells 
were detached from the culture dish with 0.05% trypsin and 
0.01% EDTA (Euroclone, Italy). Trypsin activity was neutralized 
with a trypsin soybean inhibitor solution [0.5 mg/ml in phosphate 
buffered saline (PBS); GIBCO, USA].
human articular chondrocyte (hac) 
cultures
Femoral heads or femoral condyles were collected from patients 
undergoing hip or knee arthroplasty respectively, with their 
informed consent. The patients’ age ranged from 61 to 81 years 
old. All obtained samples were processed immediately after the 
surgery and the experiments were performed on cells derived 
from different donors. After washing the tissue fragment with 
sterile PBS, the articular cartilage was isolated using a sterile blade, 
minced into small pieces, and exposed to repeated cycles of diges-
tion at 37°C in serum-free Coon’s modified Ham’s F12 medium 
(Biochrom, Germany) containing 0.25% (v/v) trypsin (GIBCO, 
USA), 1  mg/ml hyaluronidase type II (Sigma Aldrich, USA), 
400  U/ml collagenase type I and 1,000  U/ml collagenase type 
II (Worthington Biochemical, USA). Recovered chondrocytes 
were expanded as adherent cells (dedifferentiated chondrocytes) 
up to 6 passages in complete medium (Coon’s modified Ham’s 
F-12 medium supplemented with 2 mM l-glutamine, 100 IU/ml 
penicillin, and 100  µg/ml streptomycin) and 10% FCS. When 
indicated, the medium was additionally supplemented with 5% 
v-PL. Culture media were changed twice a week. Cultures were 
performed at 37°C and 5% CO2.
In some experiments, dedifferentiated chondrocytes were 
transferred in suspension culture in the presence of ascorbic acid 
to allow the formation of a cartilage-like tissue (Zerega et  al., 
1999).
cell Proliferation assays
Long-term Cell Proliferation Assay—Cumulative 
Doubling Number Calculation
For determining the number of doublings of BM-MSC, AD-MSC, 
and UC-MSC in a long-term culture, after the initial selection of 
the cells (passage 0) in FCS supplemented medium, at 70–80% 
confluence, cells were detached with trypsin/EDTA solution and 
replated at the density of 7 × 104 cells for UC-MSC and 1 × 105 
cells for all the other cell types, in 60 mm Ø Petri dishes, in dupli-
cate with medium supplemented with 10% Pl-s or 10% Pl-s + 5% 
v-PL or 10% Pl-s + 1% v-PL.
The human cell lines U-937 (pro-monocytic cells growing 
in suspension), HeLa (epithelial cells with adhesion growth), 
HaCaT (keratinocytes with adhesion growth), and the animal 
cell line V79 (hamster lung fibroblasts, also growing as adher-
ent cells) were cultured with the same supplements used for the 
primary cell cultures. At each passage, cells were plated at the 
following densities: U-937, 200,000 cells/ml in T25 flask; HeLa, 
250,000 cells/plate 60 mm Ø; HaCaT, 250,000 cells/plate 60 mm 
Ø; and V79, 400,000 cells/plate 60 mm Ø.
To monitor cell proliferation, the performed cumulative 
doubling number was calculated when the cells reached the 
sub-confluence at each passage and derived at different culture 
times (every 5 days until the end of the culture corresponding to 
about 30 days) as reported into the graphics. Cells were counted 
using a cell counting chamber under the microscope without any 
staining.
Short-term Cell Proliferation Assay
For determining cell proliferation rate during a short time 
period (about 1  week), BM-MSC, HeLa, and U-937 chosen as 
representative of primary cell cultures and cell lines growing 
in adhesion and in suspension, respectively, were plated for 
BM-MSC at 50,000 cells and for Hela, at 100,000 cells/well in 
6 multi-well plates. U-937 were seeded at 100,000 cells/ml 
in T25 flask. The number of cells was determined at different time 
intervals during a week. Results were expressed as the average of 
at least duplicate independent experiments.
cell Proliferation assay for articular 
chondrocytes—crystal Violet staining
Cells were seeded in 96 multi-well plates and cultured in the pres-
ence of different medium supplements as indicated. At different 
times of the culture, after extensive washing with PBS, cells were 
stained with 50 µl staining solution [0.75% (g/ml) crystal violet 
(Sigma-Aldrich, USA), 0.35% (g/ml) NaCl, 32.3% (v/v) absolute 
ethanol, 8.64% (v/v) formaldehyde 37%] for 20  min at room 
temperature (RT). Cells were then washed five times with water 
and dried by exposing the plate to air under a chemical hood. 
To each well 100 µl eluent solution [50% (v/v) absolute ethanol 
and 1% (v/v) acetic acid] were added and the absorbance at 
595 nm measured within 10–30 min with a spectrophotometer 
AD 200 (Beckman Coulter, USA). For each experimental condi-
tion, quintuplicate assays were performed. Results were expressed 
as the average of at least three independent experiments.
cell Differentiation assays
Osteogenic Differentiation
Confluent BM-MSC and AD-MSC were cultured in osteogenic 
differentiation medium containing 10% Pl-s, 50 µg/ml ascorbic 
acid, 10  mM β-glycerophosphate and 10−7 M dexamethasone 
(all from Sigma). Negative control cultures were maintained in 
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medium containing 10% Pl-s. The medium was changed three 
times weekly and osteogenic stimulation took place for 3 weeks. 
Alizarin red S staining was performed at the end of the induction 
period. In some experiments (n = 3), parallel cell cultures were 
conducted in the presence of 10% FCS expanded cells, as stand-
ard additive for the cell culture medium.
Chondrogenic Differentiation
Dedifferentiated chondrocytes were transferred in suspension 
culture in 15 ml Falcon tubes to prevent cell attachment, but still 
ensuring cell–cell interactions, and in the presence of 100 µg/ml 
ascorbic acid (Sigma Aldrich, USA) to allow the organization 
of a cartilage matrix and the formation of a cartilage-like tissue. 
Cell aggregates were cultured with ascorbic acid for 10  days 
before being processed for histological analysis: aggregates were 
washed 3 times with PBS, fixed with 3.7% PFA for 20  min at 
4°C and embedded in paraffin. Paraffin embedded samples were 
sectioned in slices of 5–6  µm thickness. Slices were adhered 
on Superfrost Ultra Plus Slides (Thermo Scientific, Germany) 
coated with poly-l-lysine (Sigma Aldrich, USA), dewaxed to 
remove paraffin and processed for immunohistochemistry.
Sections were permeabilized with 0.2% Triton in PBS for 
10 min, treated with 4% H2O2 for 30 min at RT to inhibit endo-
genous peroxidase activity, rinsed with PBS 3 times  ×  5  min, 
incubated with hyaluronidase type II (Sigma Aldrich, USA) 
at concentration of 1 mg/ml in PBS (pH 6) for 30 min at 37°C 
and washed with PBS. After incubation with 10% normal goat 
serum in PBS for 1 h at RT to inhibit nonspecific binding, the 
sections were incubated at 4°C for 16 h with primary antibod-
ies against α-collagen type II (1:100; CIIC1-Developmental 
Studies Hybridoma Bank, University of Iowa), washed three 
times with PBS and incubated for 1 h at RT with Labeled poly-
mer HRP anti-mouse (Dako, Denmark). Sections were stained 
with 3,3′-Diaminobenzidine (DAB, Enzo Life Sciences, USA) 
for 3–5 min, counter-stained with Mayer’s hematoxylin for 2 s, 
submersed in 0.1% NaHCO3 for 1 min, and finally mounted with 
Eukitt (O. Kindler GmbH, Germany). Images were acquired by 
a microscope Axiovert 200M (Carl Zeiss, Gottingen, Germany).
Western Blot analysis
Confluent dedifferentiated chondrocytes were supplemented 
with 5% v-PL either in the presence or in the absence of bovine 
serum. At different times from the addition of the supplement, 
cells were washed with PBS and collected for western blot analysis. 
Electrophoresis was performed in reducing conditions using 25 μg 
of protein loaded on a 4–12% NuPAGE Bis-Tris gel (Invitrogen, 
Italy) as described (Ulivi et al., 2006). Primary antibodies tested 
were α-Cyclin D1 (1:250) and α-Actin (1:200) (Santa Cruz 
Biotechnology, USA), α-phospho Erk1/2 (1:1,000), α-phospho 
Akt (1:1,000) (Cell Signaling Technology, USA). Secondary HRP 
conjugated anti-mouse and anti-rabbit antibodies were both 
diluted 1:5,000 (GE Healthcare, UK), peroxidase conjugated anti 
goat antibody was diluted 1:10,000 (Jackson Immunoresearch, 
USA). ECL was purchased from GE Healthcare, UK.
Images were scanned using the Epson perfection 1260 scan-
ner (Epson, Italy) and band densities were quantified using 
the ImageJ software (http://rsbweb.nih.gov/ij/download.html). 
Western blots were performed on three different independent 
primary cultures.
Karyotype analysis
40,000 BM-MSC expanded in medium containing 10% Pl-s + 1% 
v-PL were plated in slide flasks (Thermo Fisher Scientific, 
Roskilde, Denmark) and cultured at 37°C in 5% CO2 atmosphere. 
The slide flasks were checked every day for cell growth. When 
several macroscopic colonies were visible the medium was 
replaced with 2.5  ml of fresh medium containing Colcemid 
solution (6  µg/ml; Sigma Aldrich, USA) and incubation 
continued. After 2 h, the medium was removed and replaced 
with 5 ml of hypotonic solution [tri-Sodium citrate dehydrate 
17 mM/Potassium Chloride 75 mM (1:1) solution] followed by 
an incubation of 10 min. After that 0.5 ml of fixative ethanol/
acetic acid (3:1) solution were added to the flask for 10  min 
at RT. The solution was then removed and replaced by 2.5 ml of 
fresh fixative followed by an incubation of 15 min (repeated three 
times).
Chromosome staining was performed by Q-banding tech-
nique (Quinacrine stain, DBA Italia, Italy). Each slide was 
examined and photographed under a fluorescence microscopy 
(Olympus) using software MACTYPE 5.4.1 (Apple). A minimum 
of 10 metaphases for each sample were captured and analyzed.
growth Factor Quantification
PDGF-BB and VEGF were quantified by an ELISA assay on Pl-s 
and v-PL. The adopted kits were from RayBiotech (USA) for 
PDGF-BB and from Invitrogen (USA) for VEGF, respectively. The 
assays were performed according to the manufacturer directives.
statistics
Differences between cell culture conditions were assessed by 
the non-parametric Mann–Whitney test. Statistical significance 
was accepted for any p–value <0.05. Analyses were performed 
using the SPSS package (version 21 for Windows, IBM).
The data were expressed in the graphs as mean ± SE.
resUlTs
growth Factor Quantification in the v-Pl 
and the Pl-s
v-PL and Pl-s were produced according to the protocol described 
in the Section “Materials and Methods” and outlined in Figure 1. 
An ELISA assay was performed for the quantification in the two 
culture medium supplements of PDGF-BB and VEGF as repre-
sentative indicators of platelet factors present in a relatively high 
and relatively low concentration, respectively (Table 1).
stimulation of cell Proliferation by v-Pl: 
Primary cell cultures versus cell lines
Mesenchymal stem cells derived from adult tissues (AD-MSC 
and BM-MSC) or from a fetal tissue (UC-MSC) initially isolated 
and expanded in 10% FCS (passage 0) were transferred in 
medium supplemented with Pl-s and v-PL in different relative 
ratios (10% Pl-s or 10% Pl-s + 1% v-Pl or 10% Pl-s + 5% v-PL) 
TaBle 1 | Concentrations of PDGF-BB and VEGF in the culture medium 
supplements.




Plasma-serum (Pl-s) 0.11 ± 0.06 0.02 ± 0.01
virgin-Platelet lysate (v-PL) 64.58 ± 9.10 4.35 ± 1.23
aAverage of four different preparations.
bAverage of two different preparations.
FigUre 2 | v-PL effect on cell proliferation—primary cultures. Adult tissue derived primary cells, adipose-derived mesenchymal stem cells (AD-MSC) and bone 
marrow-derived mesenchymal stem cells (BM-MSC) or fetal tissue derived cells, umbilical cord-derived MSC (UC-MSC) initially selected and expanded in medium 
supplemented with 10% FCS were transferred to media with different platelet- and plasma-derived supplements. Their proliferation rate was monitored by 
calculating the number of doublings performed during the time in culture. Number (n) of cell cultures used for the experiments is indicated on the graph for  
each cell type.
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and the cultures continued by passaging the cells before they 
reached confluence for about 30 days. By the evaluation of the 
cumulative number of population doublings performed in the 
different culture conditions, the following conclusions were 
inferred: (i) In general, cells cultured with Pl-s alone showed a 
low or no proliferation rate in comparison to cells grown with 
the combination of Pl-s and v-PL; (ii) In particular, BM-MSC 
essentially did not proliferate in the presence of Pl-s alone (about 
2 cell doublings in 30 days) whereas underwent 10.5 and 17 cell 
doublings in 10% Pl-s + 1% v-PL and 10% Pl-s + 5% v-PL culture 
medium, respectively; (iii) AD-MSC and UC-MSC performed 
about 10 doublings in 10% Pl-s and about 25 and 20 doublings 
in the presence of Pl-s and v-PL, respectively (Figure  2). For 
all three primary cultures, the observed difference in the pro-
liferation rate between the cultures performed in 10%Pl-s and 
the cultures performed in 10%Pl-s + v-PL either 1 or 5% resulted 
statistically significative. No statistically significant differences 
were observed between 10% Pl-s + 1% v-PL or 10% Pl-s + 5% 
v-PL (Table 2).
The same culture medium supplements, used in the same 
combinations as for the primary cell cultures, were tested with 
human, U937, HeLa, HaCaT, and animal V-79 cell lines. Also in 
this case, the cell proliferation was monitored by determining 
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the number of cell doublings at different culture times. v-PL was 
not required to support cell proliferation. Indeed, Pl-s alone was 
able to support human cell growth in a manner comparable to 
the different combinations of Pl-s and v-PL both for suspension 
(U-937) and adhesion (HeLa and HaCaT) cultures. Moreover, the 
human additives sustained survival and proliferation of animal 
derived cells (V-79, growing in adhesion) comparably to human 
cells (Figure  3). The statistical analysis of the different growth 
curves revealed no significant differences between the different 
culture conditions (Table 2).
v-Pl Promotes re-entry in the cell cycle 
of confluent resting cells
Confluent growth-arrested dedifferentiated HAC were main-
tained in the original culture medium supplemented with 10% 
FCS or additionally supplemented with 5% v-PL. A crystal violet 
proliferation assay was performed in parallel on both cultures 
(Figure 4 upper panel). Confluent cells treated with v-PL resumed 
proliferation, whereas the control culture maintained in FCS only 
remained quiescent and did not proliferate.
A western blot analysis of proteins extracted from control 
cells and cells treated with 5% v-PL for different times (1, 4, 
and 8 h) was performed using α-cyclin D1, α-phospho Akt, and 
α-phospho Erk1/2 antibodies. Actin was blotted as an internal 
control. After 1  h from the v-PL treatment, we observed an 
increase in the amount of phospho Akt and phospho extracel-
lular signal-regulated protein kinases 1 and 2 (Erk1/2). After 
8 h the activation of these proteins was almost completely over. 
Instead at the same time an expression of the Cyclin D1 protein 
reached its maximum. Interestingly, the western blot analysis 
also showed that these proliferation pathways were activated 
by PL not only in cells resuming proliferation but also in cells 
treated with v-PL in the absence of serum (Figure  4 bottom 
panel).
This confirmed and expanded our previous observation that 
confluent quiescent osteoblasts (Ruggiu et  al., 2013) that did 
not proliferate when maintained in serum, once exposed to the 
PL mitogenic stimulus were able to activate signal transduction 
pathways that promoted cell growth in response to the extracel-
lular signals.
TaBle 2 | Statistical comparison of culture conditions as depicted in the corresponding figures.
culture condition
cell type p-value 10% Pl-s 10% Pl-s + 1% v-Pl 10% Pl-s + 5% 
v-Pl
10% Fcs 10% Fcs +5% 
v-Pl
5% plasma +1% 
v-Pl















































































HAC 0.078 X X
Figure 6
BM-MSC 0.739 X X
HeLa 0.461 X X
U-937 0.671 X X
Figure 7
AD-MSC 0.001 X X
For each cell type, the culture conditions comparatively assessed are identified by the sign “X.”
FigUre 3 | v-PL effect on cell proliferation—cell lines. The human cell lines U937, HeLa, HaCaT, and the hamster V79 cell line were cultured in the presence of 
different platelet- and plasma-derived supplements and their proliferation rate was monitored by calculating the number of doublings performed at different culture 
times. On the contrary to the behavior of the primary cell cultures, cell lines are less responsive to the v-PL mitogenic stimulus, and the culture condition in the 
presence of only serum is permissive to the proliferation of the cells both in adhesion or in suspension. Number (n) of cell cultures used for the experiments is 
indicated on the graph for each cell type.
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v-Pl can rejuvenate a culture  
of high Passage Msc
The positive effect of v-PL on resting cells was confirmed on 
a primary culture of BM-MSC (Figure  5). Cells, isolated and 
expanded in 10% FCS for about 10 population doublings, were 
split and transferred to different culture conditions: (i) 1% v-PL; 
(ii) 10% Pl-s; and (iii) 10% Pl-s + 1% v-PL. Both the 1% v-PL 
only and the 10% Pl-s only culture conditions were not permis-
sive for the cell growth and did not support cell proliferation. 
However, the combination of the two supplements allowed a 
good proliferation rate. After about seven doublings, to half of the 
growing cells, the v-PL was removed, leaving the cells in 10% Pl-s 
only. The cells maintained in 10% Pl-s + 1% v-PL remained fully 
viable and continued to grow up to about 25 duplications. On the 
contrary, in the half culture where the mitogenic stimulus of v-PL 
was removed, the cells, after a period of adaptation to the new 
condition, stopped growing and entered a growth arrest status. 
At this point, half of this culture was maintained in 10% Pl-s only, 
whereas the other half was transferred again to 10% Pl-s + 1% 
v-PL (restoring in this way the mitogenic stimulus of the v-PL). 
When v-PL was provided, high passage growth-arrested MSC 
resumed proliferation (Figure 5).
Pl-s versus Plasma
A comparison of the efficacy of Pl-s and plasma in sustaining 
cell proliferation was performed taking advantage of primary 
cultures of BM-MSC and different cell lines growing either 
in adhesion (HeLa) or in suspension (U-937) (Figure  6). 
FigUre 4 | v-PL promotes re-entry in the cell cycle of confluent resting 
cells. Upper panel: confluent growth-arrested chondrocytes, obtained from 
cartilage biopsies and expanded in vitro in the presence of 10% FCS, were 
maintained in 10% serum or additionally supplemented with 5% v-PL.  
A crystal violet proliferation assay was performed in parallel on both cultures. 
Confluent cells treated with v-PL resumed proliferation, whereas the parallel 
control culture did not. Lower panel: Western blot analysis of proteins 
extracted from the cells treated with 5% PL probed with Cyclin D1, phospho 
Akt, phospho Erk1/2, and Actin antibodies shows that proliferation  
pathways were activated by v-PL also in the absence of serum. Number (n) 
of cell cultures used for the experiments is indicated on the graph for each 
cell type.
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Plasma- and plasma-derived serum were equally able to sustain 
cell proliferation. No statistically significant differences were 
obtained from the analysis as shown in Table 2. However, espe-
cially for BM-MSC and HeLa, both cell types growing in adhesion, 
the Pl-s was slightly more efficient than the plasma from which 
it was derived.
Population Doublings of cells cultured 
with the new supplements versus Fcs
Adipose-derived mesenchymal stem cells were initially isolated 
and expanded in a medium containing either the standard 
animal-based 10% FCS or 10% Pl-s  +  1% v-PL (Figure  7). 
Cultures were monitored for about 30 days and the population 
doublings were calculated. Cells grown with 10% FCS performed 
a significant lower number of doublings in comparison to the 
parallel culture maintained in 10% Pl-s + 1%v-PL (6 versus 22 
doublings, respectively). The observed difference was statistically 
significant (Table 3).
Differentiation Potential of cells cultured 
with the new supplements
Maintenance of the differentiation potential by the cells expanded 
in the presence of the new medium supplements was confirmed. 
Specific in  vitro assays routinely performed in the lab were 
adopted. In particular, osteogenic differentiation was tested for 
BM-MSC and AD-MSC and chondrogenic differentiation for 
dedifferentiated articular chondrocytes. To note that, in experi-
ments where we compared differentiation of MSC expanded in 
the presence of the new culture medium supplements and in the 
standard culture condition, i.e., with FCS as medium additive, 
we observed a higher extent of osteogenic differentiation in cells 
cultured with 10% Pl-s + 1%v-PL and a possible shortening of the 
time before the onset of the osteogenic differentiation.
Representative images of the Alizarin Red S staining of 
MSC and of the type II collagen immunolocalization in the 
chondrocyte culture are presented in Figure 8. In the stimu-
lated culture condition, it is clearly evident a calcium-enriched 
matrix and a type II collagen positivity for the MSC and the 
chondrocytes, respectively.
Karyotype stability of cells cultured  
with the new supplements
Cytogenetic analysis was performed on passage 2 of 3 cultures of 
BM-MSC in 10% Pl-s + 1% v-PL, in order to obtain information 
on the genetic stability of the cells grown in this condition. One 
of the cultures was also analyzed after a more extensive expansion 
in the presence of the new supplement (passage 7). The genetic 
stability was confirmed in all cultures (Figure 9; Table 3).
DiscUssiOn
In almost all studies where in vitro-expanded human MSC were 
adopted for therapeutic purposes, the main cell culture medium 
supplement was the fetal bovine serum (FBS or FCS). However, 
in this case, the use of FBS or FCS as medium supplements is 
undesirable because of the risk of transmitting animal viruses, 
prion diseases, including the bovine spongiform encephalopa-
thy (BSE) in cows, and proteins that may trigger a xenogeneic 
immune response. The use of a human autologous serum avoids 
the zoonotic infection risk, but generation of autologous serum 
has significant limitations from a manufacturing, regulatory, 
and quality assurance perspective. Indeed, the large variability 
observed with sera from different patients deters their use for 
expansion of cells intended for therapy. Moreover, it is expected 
that the supply of bovine serum will be highly diminished in the 
near future years and that research and cell factory labs will be 
forced to modify their cell culture protocols and to adopt sub-
stitutes of FBS. For these reasons, human blood PL supplements 
are gaining an increasing interest as bovine serum substitutes, 
especially when cells that eventually will be implanted in a patient 
are cultured.
Different procedures and protocols have been adopted for 
the preparation of these PL supplements (Bieback et al., 2009) 
reviewed in Pawitan (2012) and Shih and Burnouf (2015). 
In essentially all published protocols, including the recently 
published one of ours for the production of a two component 
supplement (Muraglia et  al., 2015), the final human platelet-
derived additive includes, in addition to growth factors and 
active molecules present within platelets, also a significant 
FigUre 5 | v-PL can rejuvenate a culture of high passage mesenchymal stem cells (MSC). (a) A culture of bone marrow-derived mesenchymal stem cells 
(BM-MSC) previously expanded in the presence of 10% FCS for about 10 population doublings was split in the different culture conditions. After 3 weeks, 
one part of the cells of the culture in 10% Pl-s + 1% v-PL was transferred in medium supplemented with Pl-s without v-PL. After additional passages, at a 
time that proliferation was arrested (high passage cells), part of the Pl-s culture was transferred again in medium supplemented with 10% Pl-s + 1% v-PL 
(restoring in this way, the v-PL mitogenic stimulus). As shown by the graph, 1% v-PL cannot support cell proliferation, but the addition of v-PL to high 
passage cells, maintained in the presence of Pl-s as the only supplement, rejuvenate the cells that resume proliferation. (B) A scheme is reported to 
summarize the experiment in (a).
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amount of proteins and other molecules component of plasma. 
To avoid coagulation of the plasma fibrinogen upon addition 
of the supplement to the culture medium, heparin is normally 
added as an anticoagulant agent. However, as already mentioned 
in the introduction, it has been reported by several authors that 
heparin is capable of interfering with the activity of several 
growth factors. Hemeda et al. (2013) have described that higher 
heparin concentrations impaired cellular proliferation in a dose-
dependent manner. At high heparin concentrations colony-
forming unit frequency and the in vitro differentiation toward 
adipogenic and osteogenic lineages of human BM-MSC were 
also reduced. Moreover, being of animal origin, the addition 
of heparin should be discouraged whatever possible, especially 
when the culture medium is adopted for the expansion of cells 
intended for cell therapy.
Compared to plasma, proteins and factors involved in the 
coagulation process are missing in the serum. Conflicting results 
have been reported on the use of allogenic serum, obtained by 
conventional blood coagulation or by coagulation of plasma, 
as culture medium supplement. Initial studies performed more 
than 10 years ago with human serum revealed the possibility of 
efficiently isolate and expand human BM-MSC that maintained 
their differentiation potential (Stute et  al., 2004). Shetty et  al. 
(2007) observed an increase of cell proliferation when human 
BM-MSC cultures were performed in the presence of human 
serum from whole blood compared to FCS. In the presence 
of human serum, an enhancement in the adipogenic differen-
tiation of the same cells was observed by Oreffo et  al. (1997). 
Enhancement of MSC differentiation induced by allogenic 
human serum or autologous plasma was observed also by other 
authors (Anselme et al., 2002; Yamaguchi et al., 2002). However, 
Shahdadfar (2005) reported an increased proliferation of human 
BM-MSC induced by autologous serum compared to FCS, but 
not by allogenic serum. An increase in the proliferation, but 
a less effective differentiation of human pre-adipocytes was 
observed by Koellensperger et  al. (2006). Simões et  al. (2013) 
observed an increase in the cell yield when MSC of different 
origins were cultured with human serum compared to FCS as 
medium supplement throughout passage 3 to passage 7. Recently, 
a comparable UC-MSC proliferation was shown in cultures with 
human serum from two different plasma sources as medium 
supplement, plasma removed from blood after 24 h from col-
lection and plasma devoid of cryoprecipitate (Dos Santos et al., 
2017). However, in most, if not all, of the above-cited papers 
and similar ones in the literature, a careful determination of the 
platelet factor concentration in the serum was not done and the 
adopted protocols not always guaranty the absence of platelets 
or platelet content as serum contaminants.
TaBle 3 | Karyotype stability in cells expanded in the presence of the new 
culture medium supplements.
Donor age (years) Passage Doublings Karyotype
#1 73 2 10 46, XY
#1 73 7 15 46, XY
#2 94 2 11 46, XX
#3 51 2 14 46, XX
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Here, we reported the development of two standardized lyophi-
lized cell culture medium supplements: a completely plasma-free 
platelet lysate (v-PL) obtained from extensively washed platelets 
and a platelet lysate-free serum (Pl-s) obtained by a plasma cryo-
precipitation, to remove the bulk of the fibrinogen molecules, 
followed by a calcium-mediated coagulation, to remove the 
residual fibrinogen. Characterization of these two products and 
investigation on their biological activity when used as cell culture 
supplements lead us to conclude that v-PL recruited quiescent, 
and even differentiated or high passage growth-arrested cells 
back to the cell cycle by activating the cell proliferation machinery 
(ERK and AKT phosphorylation, Cycline D1 induction, etc.). 
Instead, v-PL was unable to support cell proliferation unless the 
plasma or serum components were also present. These observa-
tions are in agreement with the interesting results obtained with 
primary cultures of monkey arterial smooth muscle cells (Ross 
et  al., 1974) and Swiss mouse 3T3 cells, embryo derived cells 
FigUre 6 | Comparison of Pl-s and plasma as medium supplements. Human primary bone marrow-derived mesenchymal stem cells (BM-MSC) and human cell 
lines growing either in adhesion (HeLa) or in suspension (U-937) were cultured either with Pl-s or plasma as medium supplements. Cell proliferation was determined 
by direct cell counting. Number (n) of cell cultures used for the experiments is indicated on the graph for each cell type.
FigUre 7 | Growth rate of cells cultured with the new supplements. The 
combined effect of Pl-s and v-PL on cell growth was tested primary cultures 
of adipose-derived mesenchymal stem cells (AD-MSC) and compared to the 
control condition where cells were grown with the standard supplement 
FCS. The proliferation rate was monitored through the evaluation of the 
cumulative population doublings performed by the two parallel cultures. 
Number (n) of cell cultures used for the experiments is indicated on the 
graph for each cell type.
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FigUre 9 | Representative karyotype of a passage 2 bone-marrow derived mesenchymal stem cells culture. Analyses of more than 10 metaphases revealed a 
normal 46 XX karyotype.
FigUre 8 | Maintenance of the differentiation potential by cells cultured in 
the presence of v-PL and Pl-s. (a,B,e,F) Primary cultures of adipose-derived 
mesenchymal stem cells (AD-MSC) (passage 2) cultured in 10%Pl-s + 1%v-
PL (a,B) or 10% FCS (e,F); (c,D,g,h) primary cultures of bone marrow-
derived mesenchymal stem cells (BM-MSC) (passage 2) cultured in 
10%Pl-s + 1%v-PL (c,D) or 10% FCS (g,h); (a,c,e,g) cells osteogenically 
induced; (B,D,F,h) not osteogenically induced control cells. (i,l) Human 
articular chondrocytes cultured as adherent dedifferentiated cells [(i) scale 
bar 200 µm] and transferred to suspension cultures [(l) scale bar 50 µm] 
stained with antibodies against αII collagen.
with a high degree of sensitivity to contact inhibition of growth 
(Todaro and Green, 1963; Vogel et al., 1978), both types of cells 
requiring platelet-derived growth factors in association with 
plasma components to sustain the cell growth, where platelet 
factors alone did not promote proliferation. Indeed, despite the 
fact that platelet-derived mitogens were crucial to promote the 
reentry in the cell cycle (commitment) of confluent cells of early 
passages and even of late passages of primary cultures, v-PL used 
as single component did not sustain viability and proliferation of 
either cell lines or primary cell cultures. On the contrary Pl-s was 
ineffective in quiescent resting cells, but supported proliferation 
of the same cells after v-PL treatment and of cells constitutively 
stimulated as in the case of established cell lines. In agreement 
with these findings, the combination of the two components 
was highly effective in supporting proliferation of primary cell 
cultures at a higher level than FBS in control cultures, whereas 
the Pl-s added to the medium as a single component sustained the 
growth of several human cell lines in adhesion or in suspension 
at a growth rate comparable to the one of FBS control cultures. 
These results are in line with previous studies, dated back to 
almost 40  years, where virally transformed cells grew well in 
plasma-derived serum without the need of exogenous platelet 
extract, whereas malignant cells of mesodermal origin directly 
derived from tumors showed a range of dependence on platelet-
derived factors (Currie, 1981).
When we determined the efficiency of Pl-s and the plasma 
from which it was derived with regard to the ability to sustain 
cell proliferation in cultures of both primary cells and cell lines, 
14
Muraglia et al. Platelet- and Plasma-Derived Supplements
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org November 2017 | Volume 5 | Article 66
reFerences
Andress, D. L. (1995). Heparin modulates the binding of insulin-like growth 
factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. 
J. Biol. Chem. 270, 28289–28296. 
Anselme, K., Broux, O., Noel, B., Bouxin, B., Bascoulergue, G., Dudermel, A.-F., 
et  al. (2002). In vitro control of human bone marrow stromal cells for bone 
tissue engineering. Tissue Eng. 8, 941–953. doi:10.1089/107632702320934047 
Ayache, S., Panelli, M. C., Byrne, K. M., Slezak, S., Leitman, S. F., Marincola, F. M., 
et al. (2006). Comparison of proteomic profiles of serum, plasma, and modified 
media supplements used for cell culture and expansion. J. Trans. Med. 4, 40. 
doi:10.1186/1479-5876-4-40 
Balk, S. D., Whitfield, J. F., Youdale, T., and Braun, A. C. (1973). Roles of calcium, 
serum, plasma, and folic acid in the control of proliferation of normal and 
Rous sarcoma virus-infected chicken fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 
70, 675–679. doi:10.1073/pnas.70.3.675 
Bieback, K., Hecker, A., Kocaömer, A., Lannert, H., Schallmoser, K., Strunk, D., 
et  al. (2009). Human alternatives to fetal bovine serum for the expansion of 
mesenchymal stromal cells from bone marrow. Stem Cells 27, 2331–2341. 
doi:10.1002/stem.139 
Bottio, T., Pittarello, G., Bonato, R., Fagiolo, U., and Gerosa, G. (2003). Life-
threatening anaphylactic shock caused by porcine heparin intravenous infu-
sion during mitral valve repair. J. Thorac. Cardiovasc. Surg. 126, 1194–1195. 
doi:10.1016/S0022-5223(03)00813-4 
Capelli, C., Gotti, E., Morigi, M., Rota, C., Weng, L., Dazzi, F., et  al. (2011). 
Minimally manipulated whole human umbilical cord is a rich source of clini-
cal-grade human mesenchymal stromal cells expanded in human platelet lysate. 
Cytotherapy 13, 786–801. doi:10.3109/14653249.2011.563294 
Cavari, S., Ruggiero, M., and Vannucchi, S. (1993). Antiproliferative effects of 
heparin on normal and transformed NIH/3T3 fibroblasts. Cell Biol. Int. 17, 
781–786. doi:10.1006/cbir.1993.1140 
Copland, I. B., Garcia, M. A., Waller, E. K., Roback, J. D., and Galipeau, 
J. (2013). The effect of platelet lysate fibrinogen on the functionality of MSCs in 
immunotherapy. Biomaterials 34, 7840–7850. doi:10.1016/j.biomaterials.2013. 
06.050 
Currie, G. A. (1981). Platelet-derived growth-factor requirements for in  vitro 
proliferation of normal and malignant mesenchymal cells. Br. J. Cancer 43, 
335–343. doi:10.1038/bjc.1981.53 
Dos Santos, V. T. M., Mizukami, A., Orellana, M. D., Caruso, S. R., da Silva, F. B., 
Traina, F., et al. (2017). Characterization of human AB serum for mesenchymal 
stromal cell expansion. Transfus. Med. Hemother. 44, 11–21. doi:10.1159/ 
000448196 
Gajdusek, C., DiCorleto, P., Ross, R., and Schwartz, S. M. (1980). An endothelial 
cell-derived growth factor. J. Cell Biol. 85, 467–472. doi:10.1083/jcb.85.2.467 
Gilotti, A. C., Nimlamool, W., Pugh, R., Slee, J. B., Barthol, T. C., Miller, E. A., 
et al. (2014). Heparin responses in vascular smooth muscle cells involve cGMP- 
dependent protein kinase (PKG). J. Cell. Physiol. 229, 2142–2152. doi:10.1002/
jcp.24677 
Gospodarowicz, D., and Ill, C. R. (1980). Do plasma and serum have different 
abilities to promote cell growth? Proc. Natl. Acad. Sci. U.S.A. 77, 2726–2730. 
doi:10.1073/pnas.77.5.2726 
Handschin, A. E., Trentz, O. A., Hoerstrup, S. P., Kock, H. J., Wanner, G. A., and 
Trentz, O. (2005). Effect of low molecular weight heparin (dalteparin) and 
fondaparinux (Arixtra) on human osteoblasts in vitro. Br. J. Surg. 92, 177–183. 
doi:10.1002/bjs.4809 
Hemeda, H., Kalz, J., Walenda, G., Lohmann, M., and Wagner, W. (2013). Heparin 
concentration is critical for cell culture with human platelet lysate. Cytotherapy 
15, 1174–1181. doi:10.1016/j.jcyt.2013.05.006 
Huang, Q., Xu, T., Wang, G.-Y., Huang, J.-F., Xia, H., Yin, R., et al. (2012). Species-
specific identification of ruminant components contaminating industrial crude 
porcine heparin using real-time fluorescent qualitative and quantitative PCR. 
Anal. Bioanal. Chem. 402, 1625–1634. doi:10.1007/s00216-011-5590-2 
Jung, J., Moon, N., Ahn, J.-Y., Oh, E.-J., Kim, M., Cho, C.-S., et  al. (2009). 
Mesenchymal stromal cells expanded in human allogenic cord blood serum 
display higher self-renewal and enhanced osteogenic potential. Stem Cells Dev. 
18, 559–571. doi:10.1089/scd.2008.0105 
Khorana, A. A., Sahni, A., Altland, O. D., and Francis, C. W. (2003). Heparin 
inhibition of endothelial cell proliferation and organization is dependent 
on molecular weight. Arterioscler. Thromb. Vasc. Biol. 23, 2110–2115. 
doi:10.1161/01.ATV.0000090671.56682.D7 
Kobayashi, T., Watanabe, H., Yanagawa, T., Tsutsumi, S., Kayakabe, M., Shinozaki, T., 
et al. (2005). Motility and growth of human bone-marrow mesenchymal stem 
cells during ex vivo expansion in autologous serum. J. Bone Joint Surg. 87, 
1426–1433. doi:10.1302/0301-620X.87B10.16160 
Kocaoemer, A., Kern, S., Klüter, H., and Bieback, K. (2007). Human AB serum 
and thrombin-activated platelet-rich plasma are suitable alternatives to fetal 
we observed a comparable activity in the two medium supple-
ments. However, a slight proliferation advantage was observed in 
cultures supplemented with the Pl-s. This was especially true for 
cells growing adherent to the Petri dish compared to cells growing 
in suspension. This finding suggests that, during the coagulation 
process, an activation of proteins and factors favoring adherence 
of proliferating cells is occurring, possibly through enzymatic 
proteolysis.
The use of the two combined products allowed to establish 
cell cultures from tissue biopsies or aspirates in complete 
absence of animal components and to in vitro expand different 
types of cells, intended for cell therapy in humans, maintain-
ing their differentiation potential and without introducing 
karyotype alterations. These cells include, but are not limited 
to, MSC derived from bone marrow, adipose or cord blood, 
and articular chondrocytes. To note is that this not only could 
consent to perform cell therapies with cells expanded in a safer 
conditions (absence of animal components in the medium) but, 
in some cases, could allow to isolate and expand transplant-
able cells otherwise not achievable with conventional culture 
medium supplements. This is particularly relevant in case of 
elderly patients from which conventional culture medium sup-
plements often do not permit to obtain an adequate number 
of cells.
eThics sTaTeMenT
Ethics Committee of Ospedale Policlinico San Martino has 
approved the use of samples derived from the human patients 
as waste material from surgical interventions in the field of 
orthopedic and plastic surgery and destined for incineration.
aUThOr cOnTriBUTiOns
MM and RC conceived and designed the work; AM, VTN, MN, 
MM performed the experiments and elaborated data; BD per-
formed the statistical analysis; PS, IB, MF, DC provided samples 
and reagents, RC and MM participated to the interpretation and 
critical review of the manuscript. All authors approved the final 
version of the article.
acKnOWleDgMenTs
We thank Dr. Martino Introna (AO Papa Giovanni XXIII USS 
Center of Cell Therapy “G. Lanzani” USC Hematology, Bergamo, 
Italy) for providing cultures of UC-MSC. We also thank Chiara 
Ottonello and Alessandro Salzano for technical assistance. 
Supported by the international project E! 8119 Re.Me.Pro 
EUROSTARS.
15
Muraglia et al. Platelet- and Plasma-Derived Supplements
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org November 2017 | Volume 5 | Article 66
calf serum for the expansion of mesenchymal stem cells from adipose tissue. 
Stem Cells 25, 1270–1278. doi:10.1634/stemcells.2006-0627 
Koellensperger, E., von Heimburg, D., Markowicz, M., and Pallua, N. (2006). 
Human serum from platelet-poor plasma for the culture of primary human 
preadipocytes. Stem Cells 24, 1218–1225. doi:10.1634/stemcells.2005-0020 
Le Blanc, K., Samuelsson, H., Lönnies, L., Sundin, M., and Ringdén, O. (2007). 
Generation of immunosuppressive mesenchymal stem cells in allogeneic human 
serum. Transplantation 84, 1055–1059. doi:10.1097/01.tp.0000285088.44901.ea 
Mishra-Gorur, K., and Castellot, J. J. (1999). Heparin rapidly and selectively 
regulates protein tyrosine phosphorylation in vascular smooth muscle cells. 
J. Cell. Physiol. 178, 205–215. doi:10.1002/(SICI)1097-4652(199902)178:2<205:: 
AID-JCP10>3.0.CO;2-9 
Mizuno, N., Shiba, H., Ozeki, Y., Mouri, Y., Niitani, M., Inui, T., et  al. (2006). 
Human autologous serum obtained using a completely closed bag system as 
a substitute for foetal calf serum in human mesenchymal stem cell cultures. 
Cell Biol. Int. 30, 521–524. doi:10.1016/j.cellbi.2006.01.010 
Mojica-Henshaw, M. P., Jacobson, P., Morris, J., Kelley, L., Pierce, J., Boyer, M., et al. 
(2013). Serum-converted platelet lysate can substitute for fetal bovine serum 
in human mesenchymal stromal cell cultures. Cytotherapy 15, 1458–1468. 
doi:10.1016/j.jcyt.2013.06.014 
Muraglia, A., Todeschi, M. R., Papait, A., Poggi, A., Spanò, R., Strada, P., et  al. 
(2015). Combined platelet and plasma derivatives enhance proliferation of 
stem/progenitor cells maintaining their differentiation potential. Cytotherapy 
17, 1793–1806. doi:10.1016/j.jcyt.2015.09.004 
Oreffo, R. O., Virdi, A. S., and Triffitt, J. T. (1997). Modulation of osteogenesis and 
adipogenesis by human serum in human bone marrow cultures. Eur. J. Cell 
Biol. 74, 251–261. 
Papathanasopoulos, A., Kouroupis, D., Henshaw, K., McGonagle, D., Jones, E. A., 
and Giannoudis, P. V. (2011). Effects of antithrombotic drugs fondaparinux 
and tinzaparin on in  vitro proliferation and osteogenic and chondrogenic 
differentiation of bone-derived mesenchymal stem cells. J. Orthop. Res. 29, 
1327–1335. doi:10.1002/jor.21405 
Pawitan, J. A. (2012). Platelet rich plasma in xeno-free stem cell culture: the 
impact of platelet count and processing method. Curr. Stem Cell Res. Ther. 7, 
329–335. doi:10.2174/157488812802481508 
Pisciotta, A., Riccio, M., Carnevale, G., Beretti, F., Gibellini, L., Maraldi, T., et al. 
(2012). Human serum promotes osteogenic differentiation of human dental 
pulp stem cells in vitro and in vivo. PLoS ONE 7:e50542. doi:10.1371/journal.
pone.0050542 
Rauch, C., Feifel, E., Amann, E.-M., Spötl, H. P., Schennach, H., Pfaller, W., et al. 
(2011). Alternatives to the use of fetal bovine serum: human platelet lysates as 
a serum substitute in cell culture media. ALTEX 28, 305–316. doi:10.14573/
altex.2011.4.305 
Ross, R., Glomset, J., Kariya, B., and Harker, L. (1974). A platelet-dependent serum 
factor that stimulates the proliferation of arterial smooth muscle cells in vitro. 
Proc. Natl. Acad. Sci. U.S.A. 71, 1207–1210. doi:10.1073/pnas.71.4.1207 
Ross, R., Nist, C., Kariya, B., Rivest, M. J., Raines, E., and Callis, J. (1978). 
Physiological quiescence in plasma-derived serum: influence of platelet- 
derived growth factor on cell growth in culture. J. Cell. Physiol. 97(3 Pt 2 Suppl. 1), 
497–508. doi:10.1002/jcp.1040970325 
Ruggiu, A., Ulivi, V., Sanguineti, F., Cancedda, R., and Descalzi, F. (2013). The 
effect of Platelet Lysate on osteoblast proliferation associated with a transient 
increase of the inflammatory response in bone regeneration. Biomaterials 34, 
9318–9330. doi:10.1016/j.biomaterials.2013.08.018 
Rutherford, R. B., and Ross, R. (1976). Platelet factors stimulate fibroblasts and 
smooth muscle cells quiescent in plasma serum to proliferate. J. Cell Biol. 69, 
196–203. doi:10.1083/jcb.69.1.196 
Seeger, F. H., Rasper, T., Fischer, A., Muhly-Reinholz, M., Hergenreider, E., Leistner, 
D. M., et al. (2012). Heparin disrupts the CXCR4/SDF-1 axis and impairs the 
functional capacity of bone marrow-derived mononuclear cells used for cardio-
vascular repair. Circ. Res. 111, 854–862. doi:10.1161/CIRCRESAHA.112.265678 
Shahdadfar, A., Frønsdal, K., Haug, T., Reinholt, F. P., and Brinchmann, J. E. 
(2005). In vitro expansion of human mesenchymal stem cells: choice of 
serum is a determinant of cell proliferation, differentiation, gene expres-
sion, and transcriptome stability. Stem Cells 23, 1357–1366. doi:10.1634/
stemcells.2005-0094 
Shetty, P., Bharucha, K., and Tanavde, V. (2007). Human umbilical cord blood 
serum can replace fetal bovine serum in the culture of mesenchymal stem cells. 
Cell Biol. Int. 31, 293–298. doi:10.1016/j.cellbi.2006.11.010 
Shih, D. T.-B., and Burnouf, T. (2015). Preparation, quality criteria, and properties 
of human blood platelet lysate supplements for ex vivo stem cell expansion. 
New Biotechnol. 32, 199–211. doi:10.1016/j.nbt.2014.06.001 
Simões, I. N., Boura, J. S., dos Santos, F., Andrade, P. Z., Cardoso, C. M. P., 
Gimble, J. M., et al. (2013). Human mesenchymal stem cells from the umbilical 
cord matrix: successful isolation and ex vivo expansion using serum-/xeno-free 
culture media. Biotechnol. J. 8, 448–458. doi:10.1002/biot.201200340 
Stute, N., Holtz, K., Bubenheim, M., Lange, C., Blake, F., and Zander, A. R. 
(2004). Autologous serum for isolation and expansion of human mesenchy-
mal stem cells for clinical use. Exp. Hematol. 32, 1212–1225. doi:10.1016/j.
exphem.2004.09.003 
Tanaka, Y., Ogasawara, T., Asawa, Y., Yamaoka, H., Nishizawa, S., Mori, Y., et al. 
(2008). Growth factor contents of autologous human sera prepared by different 
production methods and their biological effects on chondrocytes. Cell Biol. 
Int. 32, 505–514. doi:10.1016/j.cellbi.2007.12.012 
Tateishi, K., Ando, W., Higuchi, C., Hart, D. A., Hashimoto, J., Nakata, K., et al. 
(2008). Comparison of human serum with fetal bovine serum for expansion 
and differentiation of human synovial MSC: potential feasibility for clinical 
applications. Cell Trans. 17, 549–557. doi:10.3727/096368908785096024 
Tiozzo, R., Reggiani, D., Cingi, M. R., Bianchini, P., Osima, B., and Calandra, S. 
(1991). Effect of heparin derived fractions on the proliferation and protein syn-
thesis of cells in culture. Thromb. Res. 62, 177–188. doi:10.1016/0049-3848(91) 
90191-X 
Todaro, G. J., and Green, H. (1963). Quantitative studies of the growth of mouse 
embryo cells in culture and their development into established lines. J. Cell 
Biol. 17, 299–313. doi:10.1083/jcb.17.2.299 
Turnovcova, K., Ruzickova, K., Vanecek, V., Sykova, E., and Jendelova, P. (2009). 
Properties and growth of human bone marrow mesenchymal stromal 
cells cultivated in different media. Cytotherapy 11, 874–885. doi:10.3109/ 
14653240903188947 
Ulivi, V., Tutolo, G., Mallein-Gerin, F., Daga, A., Cancedda, R., and Cancedda, F. D. 
(2006). A common pathway in differentiation and inflammation: p38 mediates 
expression of the acute phase SIP24 iron binding lipocalin in chondrocytes. 
J. Cell. Physiol. 206, 728–737. doi:10.1002/jcp.20511 
Vannucchi, S., Pasquali, F., Fiorelli, G., Bianchini, P., and Ruggiero, M. (1990). 
Effect of heparin on proliferation and signalling in BC3H-1 muscle cells. 
Evidence for specific binding sites. FEBS Lett. 263, 137–141. doi:10.1016/0014- 
5793(90)80723-V 
Vogel, A., Raines, E., Kariya, B., Rivest, M. J., and Ross, R. (1978). Coordinate 
control of 3T3 cell proliferation by platelet-derived growth factor and plasma 
components. Proc. Natl. Acad. Sci. U.S.A. 75, 2810–2814. doi:10.1073/pnas. 
75.6.2810 
Yamaguchi, M., Hirayama, F., Wakamoto, S., Fujihara, M., Murahashi, H., Sato, N., 
et al. (2002). Bone marrow stromal cells prepared using AB serum and bFGF 
for hematopoietic stem cells expansion. Transfusion 42, 921–927. doi:10.1046/ 
j.1537-2995.2002.00149.x 
Zerega, B., Cermelli, S., Bianco, P., Cancedda, R., and Cancedda, F. D. (1999). 
Parathyroid hormone [PTH(1-34)] and parathyroid hormone-related 
protein [PTHrP(1-34)] promote reversion of hypertrophic chondrocytes to 
a prehypertrophic proliferating phenotype and prevent terminal differenti-
ation of osteoblast-like cells. J. Bone Miner. Res. 14, 1281–1289. doi:10.1359/
jbmr.1999.14.8.1281 
Conflict of Interest Statement: RC and MM are shareholders of Biorigen Srl, 
a spin off company of the University of Genoa, with an interest in Regenerative 
Medicine. All other authors declare that the research was conducted in the absence 
of any commercial or financial relationships that could be construed as a potential 
conflict of interest.
The reviewer AB and handling Editor declared their shared affiliation.
Copyright © 2017 Muraglia, Nguyen, Nardini, Mogni, Coviello, Dozin, Strada, 
Baldelli, Formica, Cancedda and Mastrogiacomo. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
